What question did this study set out to answer?

This analysis aims to assess the cost-effectiveness of pembrolizumab in combination with chemotherapy for advanced biliary tract cancer.

January 25, 2026Open Access

A cost-effectiveness analysis comparing pembrolizumab combined with chemotherapy versus chemotherapy alone for advanced biliary tract cancer: US and China perspectives.

Key Points

This analysis aims to assess the cost-effectiveness of pembrolizumab in combination with chemotherapy for advanced biliary tract cancer.
Conducted cost-effectiveness analysis across US and China perspectives.
Compared treatment costs and outcomes for pembrolizumab with chemotherapy versus chemotherapy alone.
Evaluated potential pricing strategies for decision makers.
Pembrolizumab combined with chemotherapy may not be cost-effective in either country.
The findings highlight the need for further evidence on treatment affordability.
Existing pricing strategies may require reevaluation to ensure budget impact considerations.

Abstract

In the US and China, pembrolizumab plus chemotherapy may not be a cost-effective treatment option. This study provides evidence-based pricing strategies that may benefit decision makers and clinicians as they make clinical decisions. For a better understanding of the impact on budgets and the affordability of care for patients, more evidence is required.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Zhang et al. (Thu,) studied this question.

synapsesocial.com/papers/6975b26ffeba4585c2d6deaf https://doi.org/https://doi.org/10.1371/journal.pone.0341154

Bookmark

View Full Paper